![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS NO 7672V CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 9 August 1999 CAMBRIDGE ANTIBODY TECHNOLOGY AND HUMAN GENOME SCIENCES FORM ALLIANCE IN THERAPEUTIC ANTIBODIES Major new initiative for the development of human therapeutic antibody products against genomics targets Melbourn, UK and Rockville, MD, USA Cambridge Antibody Technology Group plc ("CAT") (LSE: CAT) today announces a collaborative agreement with Human Genome Sciences, Inc. ("HGS") (NASDAQ: HGSI) for the development of fully human monoclonal antibody therapeutics. The alliance will harness CAT's expertise in the generation and optimisation of fully human monoclonal antibodies for up to three target human proteins identified by and proprietary to HGS. CAT will use its high throughput antibody isolation technologies to rapidly generate high affinity, fully human monoclonal antibodies specific for HGS proteins, to explore their role in a multitude of disease indications for the development of novel therapeutics. The initial focus will be on a fast-track proprietary antigen that HGS has discovered through its genomics programs. William A. Haseltine, PhD., Chairman and Chief Executive Officer of Human Genome Sciences said, "We are delighted to initiate a collaboration with Cambridge Antibody Technology. Combining the technologies of our two companies is a natural. We are experts in the identification of hundreds of novel human proteins that are found on the surface of cells, tissues and organs; they are experts in identifying large numbers of human antibodies that recognize such proteins that may be useful as drugs and other pharmaceutical products. This is our second Transatlantic alliance with a biotechnology company, reflecting the increasing strength of this sector of the European economy. HGS is a pioneer in seeking out such collaborations". Commenting on the alliance, Dr David Chiswell, CAT's Chief Executive Officer said, "The potential to develop novel therapeutic products by combining Human Genome Sciences' unique genomics expertise with CAT's capacity for rapid generation of fully human antibodies is extremely exciting. In fact, an early demonstration of the power of combining two such powerful technologies is evident in that CAT has already identified more than 400 different human antibodies that bind to HGS' first target, many of which are high affinity and/or biologically active. Such a large number of potential product candidates could not be generated by any other approach." CAT would receive milestone and royalty payments on products and will receive research support funding. CAT and its partners have already initiated clinical trials on three human antibodies, targeting TNFa for rheumatoid arthritis, IL-12 for autoimmune disease and TGFb2 for ocular fibrosis. For Further Information Contact: Human Genome Sciences Kate de Santis, Director, Investor Relations Tel: +1 301 309 8504 Cambridge Antibody Technology Group plc Dr David Chiswell, Chief Executive Officer Dr Debbie Allen, Business Development Manager Diane Mellett, VP Legal Affairs Tel: +44 (0) 1763 263233 HCC De Facto (press enquiries) City/Financial, Rebecca Hennessy Trade/Science, Nikul Odedra Tel: +44 (0) 171 496 3300 END MSCALLSDTFIAIAA
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions